TME Pharma
A clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers.
The German company’s oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair.
Latest TME Pharma News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze